B+
Bull case
20%
Probability
Target price
$2.00
Analysis reference price unavailable
Analysis 2026-07-28 · RankAlpha Sentiment Codex
CDIO
Cardio DiagnosticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.62
Analysis reference price unavailable
Analysis 2026-07-28 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.85
Analysis reference price unavailable
Analysis 2026-07-28 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-28
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+27.2
Score
AI commentary
Headlines are active but mainly promotional awareness and commercialization coverage. Social, options, short-interest, employee-sentiment, and analyst-revision data are unavailable. The deterministic prior is modestly positive, but the peer set is loose, forward visibility is limited, and financing risk supports a tentative monitoring view rather than high-conviction positioning.
RankAlpha Sentiment Codex - 2026-07-28
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-10-18eventReimbursement conversion remains the key proof pointHigh impact
The February investor presentation cited $854 final CMS payment rates for both tests, ongoing Medicare coverage, expected out-of-network billing, and commercial-payer pilots; conversion into reimbursed volume remains unconfirmed [#8-K-2026-02-19].
2026-10-18catalystFinancing access and dilution remain dominant risksHigh impact
Q1 2026 filing context indicates very low revenue, continued operating losses and cash use, alongside additional ATM share issuance after year-end. Financing availability and dilution remain more actionable than commercialization claims [#10-Q-2026-05-15] [#SEC-10Q-2026-05-15].
2027-07-20catalystCapacity and international partnerships require repeat-volume validationHigh impact
The company presentation described a recently launched internal CLIA lab, approximately 30% initial COGS reduction, and India partnerships with Aimil and Dr. Lal PathLabs. Sustained test volume and revenue conversion remain unconfirmed [#8-K-2026-02-19].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-28 • Updated nightlySource: Internal modelMethodology